Gender-dependent accumulation of ceramides in the cerebral cortex of the APPSL/PS1Ki mouse model of Alzheimer's disease

Neurobiology of Aging

Volumn 31, Issue 11, 2010, Pages 1843-1853

  Barrier, Laurence ^a   Ingrand, Sabrina ^a   Fauconneau, Bernard ^a   Page, Guylène ^a  

^a Research Group on Brain Aging   (France)

Author keywords

Alzheimer disease; Brain; Ceramides; Galactosylceramides; Gender; Sphingomyelin; Sulfatides; Transgenic mice

Indexed keywords

CERAMIDE; GALACTOSYLCERAMIDE; HYDROXY FATTY ACID; SPHINGOMYELIN; SULFATIDE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; LIPID ANALYSIS; LIPID BRAIN LEVEL; LIPID METABOLISM; LIPID STORAGE; MALE; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CERAMIDES; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; GALACTOSYLCERAMIDES; GENE KNOCK-IN TECHNIQUES; MALE; MICE; MICE, TRANSGENIC; SEX FACTORS; SPHINGOMYELINS; SULFOGLYCOSPHINGOLIPIDS;

EID: 77956928859     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.10.011     Document Type: Article

References (54)

1. Alderson N.L., Maldonado E.N., Kern M.J., Bhat N.R., Hama H. FA2H-dependent fatty acid 2-hydroxylation in postnatal mouse brain. J. Lipid Res. 2006, 47:2772-2780.
2. Bandaru V.V.R., Troncoso J., Wheeler D., Pletnikova O., Wang J., Conan K., Haughey N.J. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol. Aging 2007, doi:10.1016/j.neurobiolaging.2007.07.024.
3. Barrier L., Ingrand S., Piriou A., Touzalin A., Fauconneau B. Lactic acidosis stimulates ganglioside and ceramide generation without sphingomyelin hydrolysis in rat cortical astrocytes. Neurosci. Lett. 2005, 385:224-229.
4. Barrier L., Ingrand S., Damjanac M., Rioux Bilan A., Hugon J., Page G. Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer's disease. Neurobiol. Aging 2007, 28:1863-1872.
5. Blanchard V., Moussaoui S., Czech C., Touchet N., Bonici B., Planche M., Canton T., Jedidi I., Gohin M., Wirths O., Bayer T.A., Langui D., Duyckaerts C., Tremp G., Pradier L. Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp. Neurol. 2003, 184:247-263.
6. Bodennec J., Koul O., Aguado I., Brichon G., Zwingelstein G., Portoukalian J. A procedure for extraction of sphingolipid classes by solid-phase extraction on aminopropyl cartridges. J. Lipid Res. 2000, 41:1524-1531.
7. Boggs J.M., Koshy K.M., Rangaraj G. Influence of structural modifications on the phase behavior of semi-synthetic cerebroside sulfate. Biochim. Biophys. Acta 1988, 938:361-372.
8. Casas C., Sergeant N., Itier J.M., Blanchard V., Wirths O., van der Kolk N., Vingtdeux V., van de Steeg E., Ret G., Canton T., Drobecq H., Clark A., Bonici B., Delacourte A., Benavides J., Schmitz C., Tremp G., Bayer T.A., Benoit P., Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Aβ42 accumulation in a novel Alzheimer transgenic model. Am. J. Pathol. 2004, 165:1289-1300.
9. Chen S., Lee J.M., Zeng C., Chen H., Hsu C.Y., Xu J. Amyloid beta peptide increases DP5 expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes. J. Neurochem. 2006, 97:631-640.
10. Childs C.E., Romeu-Nadal M., Burdge G.C., Calder P.C. Gender differences in the n-3 fatty acid content of tissues. Proc. Nutr. Soc. 2008, 67:19-27.
11. Coles L., Hay J.B., Gray G.M. Factors affecting the glycosphingolipid composition of murine tissues. J. Lipid Res. 1970, 11:158-163.
12. Cutler R.G., Kelly J., Sorie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J..C., Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2070-2075.
13. Damjanac M., Rioux Bilan A., Paccalin M., Pontcharraud R., Fauconneau B., Hugon J., Page G. Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 2008, 29:354-367.
14. Dubrac S., Lear S.R., Ananthanarayanan M., Balasubramaniyan N., Bollineni J., Shefer S., Hyogo H., Cohen D.E., Blanche P.J., Krauss R.M., Batta A.K., Salen G., Suchy F.J., Maeda N., Erickson S.K. Role of CYP27A in cholesterol and bile metabolism. J. Lipid Res. 2005, 46:76-85.
15. Fratiglioni L., Launer L.J., Andersen K., Breteler M.M., Copeland J.R., Dartigues J.F., Lobo A., Martinez-Lage J., Soininen H., Hofman A. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:10-15.
16. Grimm M.O., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., Tschäpe J.A., De Strooper B., Müller U., Shen J., Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 2005, 7:1118-1123.
17. Fewou S.N., Büssow H., Schaeren-Wiermers N., Vanier M.T., Macklin W.B., Gieselmann V., Eckhardt M. Reversal of non-hydroxy: α-hydroxy galactosylceramide ratio and unstable myelin in transgenic mice overexpressing UDP-galactose: ceramide galactosyltransferase. J. Neurochem. 2005, 94:469-481.
18. Han X., Holtzman D.M., McKeel D.W., Kelley J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 2002, 82:809-818.
19. Hannun Y.A., Obeid L.M. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 2002, 277:25847-25850.
20. Heverin M., Bogdanovic N., Lütjohann D., Baye T., Pikuleva I., Bretillon L., Diczfalusy U., Winblad B., Björkhem I. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J. Lipid Res. 2004, 45:186-193.
21. Higgins G.A., Jacobsen H. Transgenic mouse models of Alzheimer's disease: phenotype and application. Behav. Pharmacol. 2003, 14:419-438.
22. Jana A., Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J. Biol. Chem. 2004, 279:51451-51459.
23. Jorm A.F., Jolley D. The incidence of dementia: a meta-analysis. Neurology 1998, 51:728-733.
24. Katsel P., Li C., Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?. Neurochem. Res. 2007, 32:845-856.
25. Kim H.J., Chae S.C., Lee D.K., Chromy B., Lee S.C., Park Y.C., Klein W.L., Krafft G.A., Hong S.T. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. EMBO J. 2003, 17:118-120.
26. Koul O., Singh I., Jungalwala F.B. Synthesis and transport of cerebrosides and sulfatides in rat brain during development. J. Neurochem. 1988, 50:580-588.
27. Kracun I., Kalanj S., Talan-Hranilovic J., Cosovic C. Cortical distribution of gangliosides in Alzheimer's disease. Neurochem. Int. 1992, 20:433-438.
28. Ladisch S., Gillard B. A solvent partition method for microscale ganglioside purification. Anal. Biochem. 1985, 146:220-231.
29. Lofgren H., Pascher I. Molecular arrangements of sphingolipids. The monolayer behaviour of ceramides. Chem. Phys. Lipids 1977, 20:273-284.
30. Lütjohann D., Brzezinka A., Barth E., Abramowski D., Staufenbiel M., von Bregmann K., Beyreuther K., Multhaup G., Bayer T.A. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J. Lipid Res. 2002, 43:1078-1085.
31. Marcus J., Honigbaum S., Shroff S., Honke K., Rosenbluth J., Dupree J.L. Sulfatide is essential for the maintenance of CNS myelin and axone structure. Glia 2006, 53:372-381.
32. Marks N., Berg M.J., Saito M., Saito M. Glucosylceramide synthase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: consequences to morphology and viability on enzyme suppression in cultured primary neurons. Brain Res. 2008, 1191:136-147.
33. Matsuda J., Kido M., Tadano-Aritomi K., Ishizuka I., Tominaga K., Toida K., Takeda E., Suzuki K., Kuroda Y. Mutation in saposin D domain of sphingolipid activator protein gene causes urinary system defects and cerebellar Purkinje cell degeneration with accumulation of hydroxy fatty acid-containing ceramide in mouse. Hum. Mol. Genet. 2004, 13:2709-2723.
34. Maynard C.J., Cappai R., Volitakis I., Cherny R.A., Masters C.L., Li Q., Bush A.I. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer β-amyloid pathology. J. Inorg. Biochem. 2006, 100:952-962.
35. Mizutani, Y., Kihara, A., Chiba, H., Tojo, H., Igarashi, Y., 2008. Synthesis of 2-hydroxy-ceramide by ceramide synthase family members: enzymatic basis for the preference of fatty acid chain length in cultured cell models. J. Lipid Res., doi:10.1194/jlr.M800158-JLR200.
36. Morales A., Lee H., Goñi F.M., Kolesnick R., Fernandez-Checa J.C. Sphingolipids and cell death. Apoptosis 2007, 12:923-939.
37. Muller D.N., Schmidt C., Barbosa-Sicard E., Wellner M., Gross V., Hercule H., Markovic M., Honeck H., Luft F.C., Schunck W. Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetranoic acid formation. Biochem. J. 2007, 403:109-118.
38. Ngamukote S., Yanagisawa M., Ariga T., Ando S., Yu R.K. Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. J. Neurochem. 2007, 103:2327-2341.
39. Page G., Rioux Bilan A., Ingrand S., Lafay-Chebassier C., Pain S., Pérault Pochat M.C., Bouras C., Bayer T.A., Hugon J. Activated PKR and neuronal death in models of Alzheimer's disease. Neuroscience 2006, 139:1343-1354.
40. Pettus B.J., Chalfant C.E., Hannun Y.A. Ceramide in apoptosis: an overview and current perspectives. Biochim. Biophys. Acta 2002, 1585:114-125.
41. Puglielli L., Ellis B.C., Saundersn A.J., Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J. Biol. Chem. 2003, 278:19777-19783.
42. Riboni L., Viani P., Bassi R., Prinetti A., Tettamanti G. The role of sphingolipids in the process of signal transduction. Prog. Lipid Res. 1997, 36:153-195.
43. Satoi H., Tomimoto H., Ohtani R., Kitano T., Kondo T., Watanabe M., Oka N., Akiguchi I., Furuya S., Hirabayashi Y., Okazaki T. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 2005, 130:657-666.
44. Schaeren-Wiemers N., van der Bijl P., Schwab M.E. The UDP-galactose: ceramide galactosyltransferase: expression pattern in oligodendrocytes and Schwann cells during myelination and substrate preference for hydroxyceramide. J. Neurochem. 1995, 65:2267-2278.
45. Schäfer S., Wirths O., Multhaup G., Bayer T.A. Gender-dependent APP processing in a transgenic mouse model of Alzheimer's disease. J. Neural. Transm. 2007, 114:387-394.
46. Schenk M., Carpinteiro A., Grassmé H., Lang F., Gulbins E. Ceramide: physiological and pathophysiological aspects. Arch. Biochem. Biophys. 2007, 462:171-175.
47. Svennerholm L., Gottfries C.G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J. Neurochem. 1994, 62:1039-1047.
48. Tadano-Aritomi K., Hikita T., Fujimoto H., Suzuki K., Motegi K., Ishizuka I. Kidney lipids in galactosylceramide synthase-deficient mice: absence of galactosylsulfatide and compensatory increase in more polar sulfoglycolipids. J. Lipid Res. 2000, 41:1237-1243.
49. Tamboli I.Y., Prager K., Barth E., Heneka M., Sandhoff K., Walter J. Inhibition of glycosphingolipid biosynthesis reduces secretion of the β-amyloid precursor protein and amyloid β-peptide. J. Biol. Chem. 2005, 280:28110-28117.
50. Van Blitterswijk W.J., van der Luit A.H., Caan W., Verheij M., Borst J. Enzymes that regulate lipid metabolism in cell signalling. Biochem. Soc. Trans. 2001, 29:819-824.
51. Vos J.P., Lopez-Cardoso M., Gadella B.M. Metabolic and functional aspects of sulfogalactolipids. Biochim. Biophys. Acta 1994, 1211:125-149.
52. Wang G., Silva J., Dasgupta S., Bieberich E. Long-chain ceramide is elevated in presenilin1 (PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes. Glia 2008, 56:449-456.
53. Wirths O., Breyhan H., Schäfer S., Roth C., Bayer T.A. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. Neurobiol. Aging 2008, 29:891-901.
54. Zhang Y., McLaughlin R., Goodyer C., LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide 1-42 through p53 and Bax in cultured primary human neurons. J. Cell Biol. 2002, 156:519-529.